Artal Group S.A. Lava Therapeutics Nv Transaction History
Artal Group S.A.
- $214 Million
- Q3 2024
Shares
1 transactions
Others Institutions Holding LVTX
# of Institutions
28Shares Held
3.61MCall Options Held
32.9KPut Options Held
500-
Redmile Group, LLC San Francisco, CA2.07MShares$2.16 Million0.23% of portfolio
-
Bruce & Co., Inc. Chicago, IL772KShares$802,7480.53% of portfolio
-
Sphera Funds Management Ltd. Tel Aviv, L3146KShares$152,3150.04% of portfolio
-
Two Sigma Investments, LP New York, NY103KShares$106,8760.0% of portfolio
-
Pathway Financial Advisors LLC103KShares$106,6000.04% of portfolio
About LAVA Therapeutics NV
- Ticker LVTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,797,700
- Market Cap $26.8M
- Description
- LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer...